Since the establishment of a central research laboratory in 1982, GC Pharma has led the biologics market including recombinant proteins. As a result, it succeeded in developing a novel influenza vaccine, a seasonal flu vaccine, third-generation gene recombination therapy for hemophilia, and the world’s second-ever treatment for Hunter syndrome with its own technologies. In addition, it developed IV-Globulin (IVIG), Albumin, Hepa-Big, Antithrombin-III, Greenplast, etc., many of which have grown as main revenue sources of the company. In order to expand and systematize the existing R&D activities, the R&D laboratory was divided into RED Division and MSAT Division to give impetus to new drug development.
RED Division is to discover early drug candidates and conduct early process research and non-clinical development to confirm efficacy and toxicity whereas MSAT Division is to conduct late process research. By splitting the R&D laboratory into these two divisions, GC Pharma desires to create effective R&D synergy effect to take a leap as a global pharmaceutical company. RED Division established a bridgehead for global new drug development by adding business development work to license in and carry out joint research for diverse novel drug candidates, to new biomedicine R&D projects based on life science technologies and innovative novel drug candidate development projects. MSAT Division is in charge of late process development for substances for which early process development has been completed. The Division is contributing to accelerating new drug development by improving the speed and efficiency of new drug development.
The new GC Pharma R&D Center, established in 2013 as the largest pharmaceutical R&D facility in Korea, consists of two floors underground and five above, and sprawls over a total floor area of 28,510 m². It features facilities dedicated to new drug development, testing manufacturing processes and producing non-clinical testing agents, a cutting-edge animal testing lab, and specialized analysis facilities. By completely separating the research and office areas, the center maximizes efficiency in R&D activities. Thanks to the state-of-the-art research facilities and equipment, the center has quickly positioned itself as the forward base and chief engine for GC Pharma’s R&D innovations.